Dovonex

Dovonex is a brand name of calcipotriene topical, approved by the FDA in the following formulation(s):

DOVONEX (calcipotriene - cream; topical)

• 
  Manufacturer: LEO PHARM
  
  Approval date: July 22, 1996
  
  Strength(s): 0.005% ^[RLD]

DOVONEX (calcipotriene - solution; topical)

• 
  Manufacturer: LEO PHARM
  
  Approval date: March 3, 1997
  
  Strength(s): 0.005% ^[RLD][AT]

Has a generic version of Dovonex been approved?

A generic version of Dovonex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dovonex and have been approved by the FDA:

calcipotriene solution; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: May 6, 2008
  
  Strength(s): 0.005% ^[AT]


• 
  Manufacturer: G AND W LABS INC
  
  Approval date: March 24, 2011
  
  Strength(s): 0.005% ^[AT]


• 
  Manufacturer: HI TECH PHARMA
  
  Approval date: November 19, 2009
  
  Strength(s): 0.005% ^[AT]


• 
  Manufacturer: TOLMAR
  
  Approval date: November 20, 2009
  
  Strength(s): 0.005% ^[AT]

Note: No generic formulation of the following product is available.

• calcipotriene - cream; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dovonex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystalline form of a vitamin D analogue
  Patent 5,763,426
  Issued: June 9, 1998
  Inventor(s): Hansen; Erik Torngaard & Rastrup Andersen; Niels Smidt & Ringborg; Lene Hoffmeyer
  Assignee(s): Leo Pharmaceutical Products Ltd.
  The present invention relates to calcipotriol hydrate--a new crystalline form of calcipotriol--with superior technical properties and with superior stability.
  
  Patent expiration dates:
  
  
  • June 9, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline form of a vitamin D analogue
  Patent RE39706
  Issued: June 26, 2007
  Inventor(s): Hansen; Erik Torngaard & Andersen; Niels Smidt Rastrup & Ringborg; Lene Hoffmeyer
  Assignee(s): Leo Pharma A/S
  The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability.
  
  Patent expiration dates:
  
  
  • June 9, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Dovonex Consumer Information (Drugs.com)
• Dovonex Cream Consumer Information (Wolters Kluwer)
• Dovonex Solution Consumer Information (Wolters Kluwer)
• Dovonex Consumer Information (Cerner Multum)
• Dovonex Topical Advanced Consumer Information (Micromedex)
• Dovonex AHFS DI Monographs (ASHP)
• Calcipotriene Cream Consumer Information (Wolters Kluwer)
• Calcipotriene Solution Consumer Information (Wolters Kluwer)
• Calcipotriene topical Consumer Information (Cerner Multum)
• Calcipotriene Topical Advanced Consumer Information (Micromedex)
• Calcipotriene AHFS DI Monographs (ASHP)